The purpose of this study is to see if it is safe and effective to give L-743,872 to
patients with thrush, an AIDS-related yeast infection of the mouth, that has not been cured
with fluconazole treatment.
Patients are randomized to treatment with L-743,872 at one of two doses administered
intravenously by a peripheral line once-daily. Patients are treated for 48 hours beyond
resolution of symptoms or for a maximum of 14 days. Each patient is expected to complete the
study, including the 14-day follow-up, within approximately 4 weeks. A physical examination
is performed daily during the antifungal treatment period and at the follow-up visits 7 and
14 days post-therapy. Laboratory tests of blood and urine for safety are performed every
three days during treatment and at follow-up 7 days post-therapy. Liver enzymes are drawn at
the 14-day follow-up visit.
You may be eligible for this study if you:
- Have thrush that has not responded to fluconazole treatment.
- Are 18-65 years old.